Antitumor effects of peptide HM-3 against non-small cell lung cancer xenografts in nude mice
10.3969/j.issn.1001-1978.2016.06.014
- VernacularTitle:多肽HM-3对人非小细胞肺癌裸鼠移植瘤抑制作用研究
- Author:
Haoran CHENG
;
Jiayi WANG
;
Xiaodong WU
;
Jingchao HAO
;
Yanping LUO
;
Chen LIU
;
Jialiang HU
;
Hanmei XU
- Publication Type:Journal Article
- Keywords:
peptide HM-3;
non-small cell lung canc-er;
Avastin;
angiogenesis inhibitor;
xenografts in nude mice;
tumor microenvironment;
docetaxel
- From:
Chinese Pharmacological Bulletin
2016;32(6):806-811
- CountryChina
- Language:Chinese
-
Abstract:
Aims Toevaluatethepharmacodynamic efficacy of different types of antiangiogenic agents as HM-3 on a non-small cell lung cancer xenografts tumor model .To explore the interaction between the antian-giogenic agents and the tumor microenvironment,and to offer suggestions for clinical therapy.Methods Thenon-smallcelllungcarcinomaxenograftmodelwas established in Balb/c nude mice.The model mice were treated with Docetaxel(10 mg·kg-1 )as the positive control.The mice were parallelly treated with,HM-3 at the doses of 3 mg · kg-1 and 48 mg · kg-1 and, Avastin(5 mg·kg-1 ).The parameters include tumor volume,tumor weight and immunohistochemical analy-sis.Result Animalexperimentsshowedthatdocetaxel had good anti-tumor activity.Tumor growth inhibition by tumor weight of G2 docetaxel(10 mg·kg-1 )group was 60. 80%.Tumor growth inhibition by tumor weight of G3 HM-3(3 mg·kg-1 )group,G4 HM-3(48 mg· kg-1 )group ,G4 Avastin(5 mg·kg-1 )group,were 43. 60%,-34. 80%,44. 40%,respectively.Con-clusion Theantigiogeniceffectisaffectedbytumor growth stage,tumor microenvironment and their work-ing mechanisms.Angiogenesis inhibitors HM-3 has a certain effect of inhibiting tumor growth,but to little a-vail.HM-3 shows on inhibitory effect in a dose-de-pendent manner at the doses of 0~6 mg·kg-1 .HM-3 at a high dose of 48 mg · kg-1 has no inhibitory but promoting effects on human non-small cell lung carci-noma A549 xenografts in nude mice .Special dose-effect relationship indicates that dosage should be paid attention to in the clinical use of blood vessel inhibi-tors.
